MYC and diffuse large B-cell lymphoma: Indeed, MCL1 inhibition is currently in early clinical testing for multiple myeloma and MYC positive diffuse large B-cell lymphoma (DLBCL) with promising results (Clinicaltrails.gov, NCT02992483).